Compare ADMA Biologics Inc (ADMA) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.77. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XDTE | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $44.76 |
52-Week Low | $7.60 | $36.00 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XDTE trades at $39.16, up 0.8% with a bearish technical signal from moving averages. The ETF generates weekly dividend income through covered call strategies on S&P 500 options, though recent analysis highlights NAV erosion concerns despite high yields. Support levels cluster around $38-39 with resistance at $39-40, indicating tight trading range constraints.
The fund's 20%+ dividend yield attracts income investors but faces structural risks from option strategy decay during market shifts. Analyst consensus remains cautious due to NAV performance lagging underlying index gains, requiring careful monitoring of distribution sustainability versus capital preservation trade-offs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
